Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase-Reference-Cited by-同舟云学术

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Published:2019-08-05 Issue:17 Volume:62 Page:7923-7940
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Guo Yunhang^ORCID,Liu Ye,Hu Nan,Yu Desheng,Zhou Changyou,Shi Gongyin,Zhang Bo,Wei Min,Liu Junhua,Luo Lusong,Tang Zhiyu,Song Huipeng,Guo Yin,Liu Xuesong,Su Dan,Zhang Shuo,Song Xiaomin,Zhou Xing,Hong Yuan,Chen Shuaishuai,Cheng Zhenzhen,Young Steve,Wei Qiang,Wang Haisheng,Wang Qiuwen,Lv Lei,Wang Fan,Xu Haipeng,Sun Hanzi,Xing Haimei,Li Na,Zhang Wei,Wang Zhongbo,Liu Guodong,Sun Zhijian,Zhou Dongping,Li Wei,Liu Libin,Wang Lai,Wang Zhiwei^ORCID

Funder

National Science and Technology Major Project for Drug Innovation

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.9b00687

Reference43 articles.

1. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases

2. The Src, Syk, and Tec family kinases: Distinct types of molecular switches

3. Primary B Cell Immunodeficiencies: Comparisons and Contrasts

4. Constitutive activation of Bruton's tyrosine kinase induces the formation of autoreactive IgM plasma cells

Cited by 235 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bruton’s tyrosine kinase: A promising target for treating systemic lupus erythematosus;International Immunopharmacology;2024-12

2. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21

3. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21

4. Targeted small molecule therapy and inhibitors for lymphoma;Future Medicinal Chemistry;2024-07-17

5. Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock;Blood Advances;2024-07-12